Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.

Arndt Vogel,Lorenza Rimassa,Hui-Chuan Sun,Ghassan K. Abou-Alfa,Anthony B. El-Khoueiry,David J. Pinato,Monica Daigl,Javier Sanchez Alvarez,Panos Orfanos,Michael Leibfried,Marie-Hélène Blanchet Zumofen,Vincent E. Gaillard,Philippe Merle

Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.

2020

Arndt Vogel
Lorenza Rimassa
Hui-Chuan Sun
Ghassan K. Abou-Alfa
Anthony B. El-Khoueiry
David J. Pinato
Monica Daigl
Javier Sanchez Alvarez
Panos Orfanos
Michael Leibfried
Marie-Hélène Blanchet Zumofen
Vincent E. Gaillard
Philippe Merle

4585Background: The IMbrave150 pivotal study in unresectable HCC showed superiority of atezolizumab + bevacizumab (atezo + bev) vs sorafenib for OS and PFS. Based on these data supporting first-lin...

Keywords:

Atezolizumab
Bevacizumab
Oncology
Meta-analysis
first line
Hepatocellular carcinoma
Pathology
Sorafenib
Internal medicine
clinical value
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations